BRAF targeted therapy changes the treatment paradigm in melanoma (Q42733647)

6 November 2017

1 reference

title

BRAF targeted therapy changes the treatment paradigm in melanoma (English)

1 reference

6 November 2017

2

Keith T Flaherty

1 reference

6 November 2017

1

Antoni Ribas

1 reference

6 November 2017

language of work or name

English

0 references

publication date

24 May 2011

1 reference

Nature Reviews Clinical Oncology

6 November 2017

published in

1 reference

6 November 2017

volume

8

1 reference

6 November 2017

issue

7

1 reference

6 November 2017

page(s)

426-433

1 reference

A novel transforming gene in a human malignant melanoma cell line

6 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Melanoma biology and new targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Genetic alterations in signaling pathways in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Distinct sets of genetic alterations in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

BRAF mutation predicts sensitivity to MEK inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Oncogenic Braf induces melanocyte senescence and melanoma in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Oncogenic BRAF is required for tumor growth and maintenance in melanoma models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Paradoxical activation of Raf by a novel Raf inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Lineage dependency and lineage-survival oncogenes in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Management of cutaneous melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Targeted therapies to improve tumor immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.69

Lymphocyte activation in health and disease

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21606968

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21606968

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2011.69

1 reference

release_w4rydfzyrreq5dqvrgc47drnnq

6 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/w4rydfzyrreq5dqvrgc47drnnq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference